SABCS 2014: Capecitabine Monotherapy Does Not Improve Survival in Elderly Patients With Early-Stage Breast Cancer
In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, capecitabine, which causes fewer side effects than standard chemotherapy agents, did not improve outcomes when tested as monotherapy, according to data from the phase III ICE trial presented at the 2014 San Antonio Breast Cancer Symposium (Abstract S3-04).
“We tested capecitabine as single-agent chemotherapy in elderly women with early-stage breast cancer, who also took the bisphosphonate ibandronate. After 61 months of follow-up, we found no difference in disease-free survival and overall survival between those who took capecitabine plus ibandronate and those who took ibandronate alone,” said Gunter von Minckwitz, MD, Chairman of the German Breast Group and a Professor of Gynecology at University of Frankfurt in Germany.
“Combination chemotherapy should be tried with optimal supportive care even in elderly patients,” Dr. von Minckwitz added.
“We used ibandronate because many patients at this age have osteopenia/osteoporosis, especially after chemotherapy. Bisphosphonates are also potentially preventive for breast cancer metastasis,” Dr. von Minckwitz said.
Although approximately 50% of newly diagnosed breast cancers arise in women older than 65, they are underrepresented in clinical trials, and frail elderly patients cannot be treated with conventional chemotherapy such as anthracyclines and/or taxanes, Dr. von Minckwitz explained. Subgroup analysis of an earlier trial, CALGB 49907, with metastatic breast cancer patients, showed capecitabine to be well tolerated in elderly patients, which served as a rationale for the study discussed here.
ICE Study
In the ICE study, of the 1,358 breast cancer patients aged 64 to 88 recruited between 2004 and 2008, 677 were randomly assigned to six cycles of capecitabine plus ibandronate, and 681 were randomly assigned to ibandronate only. About 80% of the patients in both groups had hormone receptor–positive disease and received a standard-of-care endocrine therapy.
The primary endpoint of the study was disease-free survival, and secondary endpoints included overall survival, compliance, and safety.
There was no difference in disease-free survival at the end of 3 years (85% in capecitabine group vs 84% in control group) and 5 years (79% in capecitabine group vs 75% in control group). There was no difference in overall survival at the end of 3 years (95% in capecitabine group vs 94% in control group) and 5 years (90% in capecitabine group vs 88% in control group).
About 8% of patients discontinued capecitabine treatment due to adverse events, and another 8% discontinued due to other reasons.
Thirty-one percent of patients in the capecitabine plus ibandronate group had grade 3 or 4 adverse events, compared with 8.7% in the ibandronate group.
This study was funded by Roche and AstraZeneca. The institution of Dr. von Minckwitz received research funding and medication for this study.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
